Vimarsana
Biggest News Aggregation in the World

Page 42 - Third Bancorp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Third Bancorp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Third Bancorp Today - Breaking & Trending Today

Axon Enterprise, Inc. (NASDAQ:AXON) Receives $335.27 Average Price Target from Analysts - Vimarsana News

Axon Enterprise, Inc. (NASDAQ:AXON) Receives $335.27 Average Price Target from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month target […]

Pinnacle Financial Partners (NASDAQ:PNFP) Price Target Cut to $102.00 by Analysts at Stephens - Vimarsana News

Pinnacle Financial Partners (NASDAQ:PNFP) Price Target Cut to $102.00 by Analysts at Stephens

Pinnacle Financial Partners (NASDAQ:PNFP – Free Report) had its target price lowered by Stephens from $109.00 to $102.00 in a report released on Thursday, Marketbeat Ratings reports. The brokerage currently has an overweight rating on the financial services provider’s stock. Several other analysts have also recently issued reports on PNFP. Barclays initiated coverage on Pinnacle […]

Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00 - Vimarsana News

Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]

Barclays Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $95.00 - Vimarsana News

Barclays Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $95.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Barclays from $100.00 to $95.00 in a report issued on Thursday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $94.00 […]

Wells Fargo & Company MN Has $40.84 Million Holdings in Invesco National AMT-Free Municipal Bond ETF (NYSEARCA:PZA) - Vimarsana News

Wells Fargo & Company MN Has $40.84 Million Holdings in Invesco National AMT-Free Municipal Bond ETF (NYSEARCA:PZA)

Wells Fargo & Company MN reduced its position in Invesco National AMT-Free Municipal Bond ETF (NYSEARCA:PZA – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,689,073 shares of the company’s stock after selling 17,619 shares during […]